BBIOBridgeBio Pharma, Inc.
$68.52+25% 1Y
$68.52
$53.2452 weeks$90.17
Is the price fair?
What BBIO's price assumes
BridgeBio Pharma, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 18.8× revenue.
18.8
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 21.5
EV / sales
Details›
- EV / EBIToperating margin −70%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 21.5
- Market capitalisation195.5 million shares, counted Aug 3, 2026
- $13.4B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks